Heparin has been recognized as a valuable anticoagulant and antithrombotic for several
decades and is still widely used in clinical practice for a variety of indications. The …

Emicizumab, a monoclonal bispecific antibody that mimics the function of activated factor VIII
(FVIII), is currently licensed for prophylactic use in patients with congenital hemophilia A with …

Background: Venous thromboembolism (VTE) has a long-term risk of recurrence, which can
be prevented by anticoagulation therapy. Methods and Results: The COMMAND VTE …

Background There has been limited data on anticoagulation strategies and long-term
recurrence in patients with venous thromboembolism (VTE) in the era of direct oral …

The optimal duration of anticoagulation for venous thromboembolism (VTE) is uncertain. In
this prespecified analysis, we used data from 2 randomized trials, which compared once …

D-dimer assay is used to stratify patients with unprovoked venous thromboembolism (VTE)
for the risk of recurrence. However, this approach was never evaluated since direct oral …

Objectives To systematically review available evidence and establish guidelines related to
the risk of developing thrombosis and the management of small animals with …

Introduction Venous thromboembolism (VTE) has a long‐term risk of recurrence, dependent
on the presence or absence of provoking risk factors at the time of the event. Objective To …

Background There is a paucity of data on real-world management strategies and clinical
outcomes of cancer-associated venous thromboembolism (VTE) in the direct oral …

Patients with unprovoked venous thromboembolism (VTE) are at high risk for recurrence.
Although rivaroxaban is effective for extended VTE treatment at a dose of 20 mg once daily …